How has been the historical performance of Brawn Biotech?

Answer:The historical performance of Brawn Biotech shows a mixed picture with limited operational activity and fluctuating financial metrics.

Breakdown:
In the financial year ending March 2023, Brawn Biotech reported net sales of 0.48 crore, with total operating income also at 0.48 crore. The total expenditure, excluding depreciation, matched the operating income at 0.48 crore, leading to an operating profit (PBDIT) of 0.24 crore after accounting for other income. The profit before tax stood at 0.22 crore, resulting in a profit after tax of 0.19 crore, which reflects a PAT margin of 39.58%. The company had an equity capital of 4.90 crore and reserves of 4.86 crore, with earnings per share (EPS) reported at 0.39. The book value per share adjusted to 21.03 in March 2023, down from previous years. On the balance sheet, total assets were recorded at 14.37 crore, with total liabilities slightly lower at 14.13 crore in March 2024. The company has not reported any long-term or short-term borrowings, indicating a debt-free status. However, cash flow results indicate a profit before tax of -1.00 crore in March 2024, suggesting challenges in generating positive cash flow from operations.